New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control
New long term data showed that Vimpat® (lacosamide) provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy.(1) In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents† and those that act on non-sodium channel-targets.(2,3)
Read more ...
Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology
Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.
Read more ...
Opening of Pharmathen's New Ultra-Modern Production Unit in Northern Greece
Marking a new era for Pharmathen's entrepreneurial and economic activity in both the Greek and the international market, the company's new ultra-modern unit at Sapes Rodopi was officially opened today. The new plant was opened by the Deputy Prime Minister, Mr Theodoros Pangalos.
Read more ...
caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project with Roche
caprotec bioanalytics GmbH has successfully completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS (Capture Compound Mass Spectrometry) technology to analyze the binding characteristics and interaction of one undisclosed drug candidate with its human target proteins.
Read more ...
Gene Therapy a step Closer to Mass Production
Researchers in Latvia and Finland have synthesised and studied a range of organic compounds able to carry genetic material into individual cells where it can remedy the diseases caused by defective genes. Still under development, these compounds are much more readily produced than the viral carriers now in use and avoid their side-effects. Most importantly, they are much more effective than other organic carrier substances developed so far.
Read more ...
Frost & Sullivan's analysts comment on India’s plan to invest in the Russian pharmaceutical industry
India is ready to invest in the Russian pharmaceutical industry, including India-Russia joint ventures, as India's Commerce and Industry Minister, Anand Sharma, said during his visit to Russia last week. Among other resources and technologies, India is very keen in developing biotechnologies, nanotechnologies and other sciences such as genomics and bioinformatics, thereby entering the Russian healthcare industry.
Read more ...
The IT @ Networking Awards 2010 - Open Competition for Healthcare IT Solutions
The IT @ Networking Awards 2010 (IT @ 2010) is an open competition for fully implemented, operable healthcare IT solutions. The goal is to raise awareness of some of the world's finest and most innovative local, regional and national healthcare IT projects.
Read more ...